Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome
Minato-ku, Tokyo, Japan, January 24 2023 — Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, announced the initiation of a phase 3 clinical study of pitolisant (), a histamine H3 receptor antagonist/inverse agonist in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS), […]
Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures
Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo; Representative Director and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, announced that it has initiated a phase 3 clinical study of a diazepam nasal spray (compound development code: NRL-1), an antiepileptic drug […]
Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan
Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo; Representative Director and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, announced that it has initiated a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant for the treatment of […]
Aculys Pharma has entered into a comprehensive collaboration agreement with KNOCK ON THE DOOR to solve social issues related to recurrent epileptic seizures
– Initiating digital transformation (DX) in clinical trial and joint research utilizing real-world data – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo; Representative Director and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, announced that it has entered into a […]
Aculys Pharma initiates collaboration with Ubie with the aim of building a “sleep ecosystem”
– a fact-finding survey of patients with sleep disorders to be conducted as a first step – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo, Representative Director and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, initiated a fact-finding survey about […]
Aculys Pharma and SUSMED have entered into a contract to conduct the world’s first clinical trial utilizing blockchain technology
– Introducing digital transformation (DX) for monitoring work and reducing new drug development costs – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo, President and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., […]
Aculys Pharma Closes US$24 Million Series B Financing
Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a new biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, today announced that it has raised a total of US$24 million in Series B Round with participation by […]
Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan
Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, announced that it has initiated a Phase 1 clinical trial of histamine H3 receptor antagonist / inverse agonist, pitolisant […]
Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®
Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray), a nasal spray approved by the FDA in the United States for the acute treatment of seizure clusters in patients with epilepsy six years of age and older. There are currently no approved nasal sprays available […]
Aculys Pharma Closes US$60 Million Series A Financing Led by SoftBank Vision Fund 2
Aculys Pharma, Inc. (“Aculys Pharma”), a new biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, today announced the closing of a US$60 million Series A financing led by SoftBank Vision Fund 2 and joined by Catalys Pacific, HBM Healthcare Investments, Global Founders Capital, Sumitomo […]